Rodenticide Poisoning

Disclaimer: This document provides comprehensive medical information for educational and reference purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment and consider individual patient circumstances. Treatment decisions should be made in consultation with toxicology specialists when appropriate. Adherence to local institutional protocols and current guidelines is essential.

Overview

• Definition: Rodenticide poisoning refers to the toxic effects resulting from the ingestion or exposure to substances designed to kill rodents. These compounds exert their effects through various mechanisms, leading to a wide range of clinical manifestations. Poisonings can be accidental (common in children, pets) or intentional (suicidal attempts).
• Epidemiology:
  • Prevalence: Rodenticides are common household and agricultural products, making exposure a significant concern. Poison control centers receive tens of thousands of calls annually related to rodenticide exposures.
  • Demographics:
    • Children (<6 years): Accidental ingestions are most common due to product accessibility and exploratory behavior. While most ingestions are small and result in minimal toxicity, the potential for severe harm necessitates prompt evaluation.
    • Adults: Intentional ingestions (suicidal attempts) account for a significant proportion of severe poisonings. Occupational exposures (pest control workers, farmers) are also possible.
    • Pets: Domestic animals, particularly dogs, are frequently poisoned by rodenticides, often after ingesting baits or poisoned rodents.
• Classification: Rodenticides are broadly classified by their active ingredients and mechanisms of action. The most clinically significant classes include:
  • Anticoagulant Rodenticides (ARs):
    • First-Generation (e.g., warfarin, coumachlor, diphacinone, chlorophacinone): Shorter half-lives, require multiple ingestions to be lethal.
    • Second-Generation ("Superwarfarins") (e.g., brodifacoum, bromadiolone, difenacoum, difethialone): Highly potent, long half-lives (weeks to months), single ingestion can be lethal, accumulate in the liver.
  • Non-Anticoagulant Rodenticides:
    • Bromethalin: Neurotoxin.
    • Cholecalciferol (Vitamin D3): Hypercalcemic agent.
    • Zinc Phosphide / Aluminum Phosphide: Releases phosphine gas.
    • Strychnine: Neurotoxin (glycine receptor antagonist).
    • Thallium: Heavy metal, multisystemic toxin (less common now due to restrictions).
    • Barium Carbonate: Cardiac and neuromuscular toxin (less common).
    • Fluoroacetate (Compound 1080): Metabolic toxin (highly restricted, rarely encountered).

Pathophysiology

• Mechanism:
  • Anticoagulant Rodenticides (ARs): Inhibit Vitamin K epoxide reductase complex (VKORC1), an enzyme essential for recycling oxidized Vitamin K back to its reduced hydroquinone form. Reduced Vitamin K is a cofactor for gamma-carboxylation of Vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S. Inhibition leads to the production of non-functional clotting factors, resulting in impaired coagulation and spontaneous hemorrhage. Second-generation ARs are more potent and have much longer half-lives due to enterohepatic recirculation and high lipid solubility.
  • Bromethalin: A neurotoxin that uncouples oxidative phosphorylation in the central nervous system (CNS) mitochondria, leading to decreased ATP production. This impairs Na+/K+ ATPase activity, causing intracellular accumulation of sodium and water, resulting in intramyelinic edema and cerebral edema. This causes increased intracranial pressure and neuronal dysfunction.
  • Cholecalciferol (Vitamin D3): Metabolized to calcitriol (1,25-dihydroxyvitamin D), which significantly increases intestinal absorption of calcium and phosphorus, and enhances bone resorption. This leads to severe hypercalcemia, hyperphosphatemia, and subsequent widespread calcification of soft tissues, particularly the kidneys (nephrocalcinosis), heart, and blood vessels, resulting in organ dysfunction.
  • Zinc Phosphide / Aluminum Phosphide: When ingested, these compounds react with stomach acid (HCl) to produce phosphine gas (PH3). Phosphine gas is a potent cellular poison that inhibits cytochrome c oxidase, leading to impaired oxidative phosphorylation and cellular hypoxia. It also causes direct corrosive injury to the GI tract and generates reactive oxygen species, leading to lipid peroxidation and multi-organ damage, particularly affecting the heart, lungs, liver, and kidneys.
  • Strychnine: A competitive antagonist of glycine receptors in the spinal cord and brainstem. Glycine is an inhibitory neurotransmitter. By blocking glycine receptors, strychnine removes inhibitory control over motor neurons, leading to uncontrolled excitation, generalized muscle spasms, and seizures in response to minimal stimuli.
• Risk Factors:
  • Accessibility: Unsecured rodenticide baits in homes, garages, or agricultural settings.
  • Curiosity/Exploration: Young children are prone to ingesting brightly colored baits.
  • Mental Health Conditions: Suicidal ideation or attempts.
  • Occupational Exposure: Pest control operators, farmers, or individuals handling large quantities without proper protective equipment.
  • Lack of Supervision: Inadequate oversight of children or vulnerable adults.
  • Poor Labeling/Storage: Incorrectly stored or unlabeled products.
  • Secondary Poisoning: Ingestion of a poisoned rodent or animal (though less common for significant human toxicity).
• Protective Factors:
  • Secure Storage: Keeping all rodenticides in their original, labeled containers, locked away and out of reach of children, pets, and vulnerable individuals.
  • Child-Resistant Packaging: Utilizing products with safety features.
  • Education: Public awareness campaigns on the dangers of rodenticides and proper handling/storage.
  • Integrated Pest Management: Emphasizing non-chemical pest control methods when possible.
  • Professional Pest Control: Hiring licensed professionals who follow safety guidelines.
  • Mental Health Support: Addressing underlying mental health issues to prevent intentional self-harm.

Clinical Presentation

Clinical presentation varies dramatically depending on the type of rodenticide, dose, and time since exposure.

Signs and Symptoms

• Anticoagulant Rodenticides (ARs):
  • Cardinal Features: Unexplained bleeding, often delayed by 24-72 hours or more after exposure, especially with superwarfarins.
  • Early Signs: Easy bruising, petechiae, epistaxis, gingival bleeding, microscopic hematuria, prolonged bleeding from minor cuts.
  • Advanced Signs: Gross hematuria, melena, hematemesis, hemoptysis, large ecchymoses, frank hemorrhage (e.g., gastrointestinal, retroperitoneal, intracranial, intra-articular), signs of hypovolemic shock.
  • Atypical Presentations: Hemorrhagic pericardial effusion, spinal epidural hematoma.
• Bromethalin:
  • Cardinal Features: Neurological dysfunction. Symptoms can be delayed 2-24 hours.
  • Early Signs: Ataxia, tremors, hind limb weakness, depression, anorexia, vomiting.
  • Advanced Signs: Muscle fasciculations, hyperthermia, seizures (tonic-clonic), nystagmus, paralysis (especially hind limb), coma, opisthotonus, death from respiratory failure.
• Cholecalciferol (Vitamin D3):
  • Cardinal Features: Signs of hypercalcemia, often delayed 12-36 hours or more.
  • Early Signs: Anorexia, lethargy, polyuria, polydipsia, vomiting, constipation, weakness.
  • Advanced Signs: Renal failure (oliguria/anuria), cardiac arrhythmias (shortened QT interval, broad T waves), pancreatitis, GI bleeding, depression, stupor, coma.
• Zinc Phosphide / Aluminum Phosphide:
  • Cardinal Features: Severe gastrointestinal distress, garlic-like odor on breath, rapid onset (minutes to hours).
  • Early Signs: Nausea, severe protracted vomiting, abdominal pain, diarrhea, eructation of gas with a characteristic "garlic" or "rotten fish" odor.
  • Advanced Signs: Dyspnea, tachypnea, pulmonary edema, hypotension, shock, cardiac arrhythmias (tachycardia, bradycardia, ventricular fibrillation), metabolic acidosis, liver and renal failure, seizures, coma.
  • Atypical Presentations: Rarely, asymptomatic presentation after very small ingestion.
• Strychnine:
  • Cardinal Features: Rapidly progressive muscle spasms and rigidity, triggered by external stimuli. Onset within 15-30 minutes.
  • Early Signs: Muscle stiffness, twitching, anxiety, restlessness.
  • Advanced Signs: Generalized tetanic muscle spasms, opisthotonus (severe hyperextension of the back), trismus (lockjaw), risus sardonicus (spasmodic grin), laryngeal spasm, respiratory arrest due to diaphragm paralysis. Consciousness is typically preserved during spasms, leading to extreme distress.

Physical Examination

• Inspection:
  • ARs: Petechiae, ecchymoses, signs of active bleeding (epistaxis, gingival bleeding, hematemesis, melena), pallor (anemia), abdominal distension (retroperitoneal or GI bleed).
  • Bromethalin: Ataxia, tremors, paresis/paralysis, altered mental status, seizures.
  • Cholecalciferol: Dehydration, lethargy, signs of renal failure.
  • Zinc Phosphide: Signs of shock (pale, cool, clammy skin), tachypnea, signs of pulmonary edema (rales/crackles), garlic odor on breath/vomitus.
  • Strychnine: Muscle rigidity, trismus, opisthotonus, risus sardonicus, visible muscle spasms (can be triggered by touch or noise).
• Palpation:
  • ARs: Tenderness over areas of internal bleeding, hematoma formation, abdominal tenderness.
  • Zinc Phosphide: Abdominal tenderness.
• Special Tests:
  • Neurological Exam: Crucial for bromethalin and strychnine poisoning. Assess gait, reflexes, muscle tone, cranial nerves, level of consciousness.
  • Cardiovascular Exam: Assess for signs of shock (tachycardia, hypotension), arrhythmias.
  • Respiratory Exam: Assess for respiratory distress, pulmonary edema.

Diagnostic Approach

History Taking

• Key Questions:
  • Substance Identification: What product was ingested? (Ask for packaging, label, active ingredients). Is it a first- or second-generation anticoagulant?
  • Amount Ingested: Best estimate of quantity.
  • Time of Ingestion: Crucial for predicting onset of symptoms and guiding decontamination.
  • Route of Exposure: Ingestion, dermal, inhalation.
  • Intent: Accidental (e.g., curious child) vs. Intentional (e.g., suicidal ideation).
  • Symptoms: Detailed chronology and description of symptoms.
  • Medical History: Pre-existing conditions (e.g., liver disease, bleeding disorders, renal disease), medications (especially anticoagulants, NSAIDs, Vitamin D supplements), allergies.
  • Environmental Context: Where was the product stored? Access by others?
  • Prior Episodes: History of self-harm or previous ingestions.
• Red Flags:
  • Any ingestion of a second-generation anticoagulant rodenticide (superwarfarin), regardless of symptoms, due to delayed and severe toxicity.
  • Evidence of deliberate self-harm.
  • Any neurological symptoms (seizures, altered mental status, paralysis, severe spasms).
  • Signs of significant bleeding or hypovolemic shock.
  • Symptoms of severe GI distress (e.g., intractable vomiting, severe abdominal pain) especially with phosphide ingestion.
  • Ingestion of unknown quantity or unknown type of rodenticide.

Laboratory Tests

• First-Line:
  • General: Complete Blood Count (CBC) with differential, electrolytes, glucose, renal function tests (BUN, creatinine), liver function tests (ALT, AST, bilirubin), urinalysis.
  • Anticoagulant Rodenticides: Prothrombin Time (PT) and International Normalized Ratio (INR), activated Partial Thromboplastin Time (aPTT). Baseline PT/INR is essential. Repeat daily for superwarfarins until stable or for at least 72 hours.
  • Cholecalciferol: Serum calcium, phosphorus, magnesium, albumin (for corrected calcium), parathyroid hormone (PTH) (often suppressed in hypercalcemia of malignancy/intoxication), 25-hydroxyvitamin D (elevated).
  • Zinc Phosphide: Arterial Blood Gas (ABG) for metabolic acidosis (often lactic acidosis), electrolytes.
  • Bromethalin/Strychnine: No specific diagnostic lab test for the toxin itself in humans; diagnosis is clinical. Labs are for supportive care and organ function.
• Confirmatory:
  • Anticoagulant Rodenticides: Factor II, VII, IX, X levels (depressed). Specific rodenticide levels in blood or urine (e.g., brodifacoum levels) are available through specialized labs but often not rapidly, and clinical management is typically guided by PT/INR.
  • Cholecalciferol: 1,25-dihydroxyvitamin D levels (elevated).
  • Zinc Phosphide: Phosphine levels in breath or blood are not routinely available or clinically useful.
  • Toxicology Screen: For unknown ingestions, a comprehensive toxicology screen may be helpful, but many rodenticides are not included or detected.
• Monitoring:
  • Anticoagulant Rodenticides: Daily PT/INR until normalized and stable. May require weeks to months of monitoring for superwarfarins.
  • Cholecalciferol: Daily serum calcium, phosphorus, renal function, ECG monitoring until normalized.
  • Zinc Phosphide: Frequent ABG, electrolytes, cardiac monitoring, renal and liver function.
  • Bromethalin/Strychnine: Neurological status, respiratory function, electrolytes, renal function.

Imaging

• Recommended:
  • Anticoagulant Rodenticides:
    • CT scan (head): If neurological changes or suspected intracranial hemorrhage.
    • Abdominal Ultrasound/CT: If significant abdominal pain or suspected retroperitoneal/GI bleeding.
    • Chest X-ray: For suspected hemothorax or pulmonary hemorrhage.
  • Cholecalciferol:
    • ECG: To assess for cardiac arrhythmias and QT interval changes due to hypercalcemia.
    • Renal Ultrasound: To assess for nephrocalcinosis or acute kidney injury.
  • Zinc Phosphide:
    • Chest X-ray: For pulmonary edema, ARDS.
    • ECG: For arrhythmias, ischemic changes.
• Advanced:
  • Bromethalin: MRI brain may show cerebral edema, white matter vacuolation, or increased intracranial pressure (non-specific, but can support diagnosis).
  • Endoscopy/Colonoscopy: In select cases of severe GI bleeding related to anticoagulant toxicity, after coagulation is normalized.

Management

Management priorities are initial stabilization, decontamination (if appropriate), antidote administration, and supportive care specific to the rodenticide type. Early consultation with a poison control center or medical toxicologist is highly recommended.

Acute Management

• Immediate:
  • Airway, Breathing, Circulation (ABCs): Assess and stabilize. Intubation and mechanical ventilation may be required for respiratory failure (e.g., strychnine, severe phosphide, bromethalin).
  • Circulatory Support: IV fluids for hypotension/shock, blood product transfusion (pRBCs, FFP, platelets) for significant hemorrhage (ARs).
  • Dermal/Ocular Decontamination: Rinse exposed skin/eyes with copious amounts of water for at least 15-20 minutes.
• Stabilization:
  • Anticoagulant Rodenticides:
    • Symptomatic Bleeding: Administer Vitamin K1 (phytonadione) intravenously or orally.
      • Minor bleeding/elevated INR: Oral Vitamin K1 2.5-10 mg daily.
      • Serious/Life-threatening bleeding: IV Vitamin K1 5-10 mg (diluted and administered slowly over 30 min to prevent anaphylactoid reaction). Repeat every 6-8 hours as needed.
      • Rapid Reversal: Prothrombin Complex Concentrate (PCC) or Fresh Frozen Plasma (FFP) for immediate factor replacement. PCC (e.g., Kcentra) is preferred over FFP due to smaller volume and faster administration. Dosage for PCC is typically weight-based (e.g., 25-50 units/kg). FFP dosage is 10-15 mL/kg.
    • Asymptomatic Ingestion (Superwarfarins): Oral Vitamin K1 1-5 mg daily for 2-4 weeks initially, then tailor duration based on INR monitoring (can require months).
  • Bromethalin:
    • Decontamination: Activated charcoal (AC) 1 g/kg (max 50 g) if within 1-2 hours of ingestion and patient is alert/protected airway. Repeat doses (multi-dose activated charcoal) may be considered due to potential enterohepatic recirculation.
    • Seizure Control: Benzodiazepines (e.g., lorazepam 2-4 mg IV, diazepam 5-10 mg IV). Propofol or barbiturates for refractory seizures.
    • Cerebral Edema: Mannitol (0.25-1 g/kg IV over 20-30 min) or hypertonic saline (3% NaCl, 5-10 mL/kg over 20-30 min) for symptomatic cerebral edema. Elevate head of bed.
  • Cholecalciferol:
    • Decontamination: Activated charcoal 1 g/kg if within 1-2 hours.
    • Hypercalcemia Management:
      • Aggressive IV Saline Hydration: 200-500 mL/hr to promote calcium excretion and correct dehydration.
      • Furosemide: After rehydration, to enhance calcium excretion (e.g., 20-40 mg IV), but use with caution to avoid dehydration.
      • Calcitonin: 4 units/kg SC/IM every 12 hours. Rapid onset (hours), short-lived effect.
      • Bisphosphonates: Pamidronate (60-90 mg IV over 2-4 hours) or Zoledronic acid (4 mg IV over 15 min). Slower onset (2-4 days), longer duration of action (weeks).
      • Glucocorticoids: Prednisone 20-60 mg daily for up to several weeks to decrease gut absorption of calcium and bone resorption.
      • Hemodialysis: For refractory hypercalcemia or severe renal failure.
  • Zinc Phosphide / Aluminum Phosphide:
    • Decontamination: Activated charcoal 1 g/kg. Do NOT induce vomiting or perform gastric lavage with water/acidic solutions, as this promotes phosphine gas release. Consider gastric lavage with sodium bicarbonate solution (to neutralize acid and reduce gas release) if presentation is very early, massive ingestion, and airway is protected, but this is controversial and should only be done by experienced personnel.
    • Supportive Care: Aggressive fluid resuscitation for shock. Avoid vasopressors if possible as phosphine sensitizes the myocardium to catecholamines; use direct-acting agents if needed.
    • Metabolic Acidosis: Sodium bicarbonate IV as needed based on ABG.
    • Arrhythmias: Magnesium sulfate (2-4g IV over 10-20 min) has been used empirically for arrhythmias thought to be related to phosphine toxicity. Treat specific arrhythmias per ACLS guidelines.
    • No specific antidote.
    • Personnel Protection: Due to phosphine gas, managing these patients requires excellent ventilation, and healthcare providers may need to wear respirators.
  • Strychnine:
    • Seizure/Spasm Control: Immediate and aggressive IV benzodiazepines are the mainstay (e.g., diazepam 5-10 mg IV, lorazepam 2-4 mg IV). Repeat as needed. Higher doses may be required.
    • Neuromuscular Blockade: If spasms are severe and refractory to benzodiazepines, intubation and non-depolarizing neuromuscular blocking agents (e.g., vecuronium, rocuronium) may be necessary to prevent rhabdomyolysis, hyperthermia, and respiratory arrest.
    • Decontamination: Activated charcoal 1 g/kg if ingestion is recent and spasms are controlled.

Chronic Management

• Pharmacological:
  • Anticoagulant Rodenticides: Long-term oral Vitamin K1 for weeks to months, guided by INR. Duration depends on the specific superwarfarin's half-life and patient's response.
  • Cholecalciferol: Bisphosphonates may be required for weeks to months to control hypercalcemia. Glucocorticoids might be used long-term.
  • Supportive Meds: For organ damage (e.g., antihypertensives for renal damage, antiarrhythmics).
• Non-pharmacological:
  • Nutritional Support: For patients with prolonged GI or neurological dysfunction.
  • Physical/Occupational Therapy: For neurological deficits following bromethalin or strychnine poisoning.
  • Psychiatric Evaluation: Mandatory for intentional ingestions to prevent recurrence.
• Monitoring:
  • Anticoagulant Rodenticides: Regular PT/INR monitoring (e.g., weekly initially, then bi-weekly/monthly) until stable off Vitamin K.
  • Cholecalciferol: Serial serum calcium, phosphorus, renal function, and vitamin D levels. Follow-up for nephrocalcinosis.
  • Other Toxins: Follow-up on organ function (e.g., liver enzymes, renal function, neurological assessment).

Treatment Algorithms

• General Acute Poisoning Algorithm:

  1. Stabilize ABCs.
  2. Identify Toxin and Amount (history, packaging).
  3. Decontamination (if appropriate and early):
     • Skin/Eye: Rinse thoroughly.
     • GI: Activated charcoal (AC) 1 g/kg (max 50g) orally for alert patients within 1-2 hours of ingestion (exceptions: phosphides). Gastric lavage rarely indicated, consider only for massive, life-threatening ingestions within 1 hour with airway protection.
  4. Administer Antidote/Specific Treatment (if available).
  5. Provide Aggressive Supportive Care.
  6. Consult Poison Control/Toxicologist.

• Specific Antidote/Treatment Guidance:

  • Anticoagulant Rodenticides (ARs):
    • Symptomatic Bleeding / INR > 6.0: IV Vitamin K1 (5-10 mg slow IV) + PCC/FFP.
    • Asymptomatic, Elevated INR (Superwarfarin): Oral Vitamin K1 (1-5 mg daily, duration depends on specific AR and INR response).
    • Asymptomatic, Normal INR (Superwarfarin): Observe, baseline PT/INR, repeat daily for 72 hours, then weekly for weeks to months. Start Vitamin K1 if INR rises.
  • Bromethalin: AC (multi-dose if high dose), seizure control (benzodiazepines), cerebral edema management (mannitol/hypertonic saline).
  • Cholecalciferol: IV fluids, furosemide (after hydration), calcitonin, bisphosphonates, glucocorticoids, hemodialysis for refractory cases.
  • Zinc Phosphide / Aluminum Phosphide: AC (avoid water lavage), aggressive fluid resuscitation, sodium bicarbonate for acidosis, magnesium for arrhythmias. Avoid vasopressors if possible.
  • Strychnine: Benzodiazepines for spasms, intubation and neuromuscular blockade for refractory spasms.

• Refractory Cases:

  • ARs: May require continued high-dose Vitamin K1 for prolonged periods, or even repeat PCC/FFP transfusions for persistent bleeding. Consider Vitamin K1 malabsorption or drug interactions.
  • Bromethalin: Refractory seizures may require continuous infusion of propofol or barbiturates. Severe cerebral edema might warrant neurosurgical intervention in rare cases, though supportive care is primary.
  • Cholecalciferol: Refractory hypercalcemia often requires hemodialysis.
  • Zinc Phosphide: Aggressive critical care support, extracorporeal membrane oxygenation (ECMO) for severe cardiorespiratory failure has been reported in case studies.

Complications

• Common:
  • ARs: Minor bleeding (epistaxis, gingival bleeding, bruising).
  • Cholecalciferol: Nausea, vomiting, lethargy.
  • Zinc Phosphide: Nausea, vomiting, abdominal pain.
• Serious:
  • ARs: Life-threatening hemorrhage (intracranial, gastrointestinal, retroperitoneal, pulmonary), hemorrhagic shock, coagulopathy.
  • Bromethalin: Status epilepticus, severe cerebral edema, permanent neurological deficits, respiratory arrest.
  • Cholecalciferol: Acute renal failure, nephrocalcinosis, cardiac arrhythmias, pancreatitis, multi-organ failure.
  • Zinc Phosphide: Cardiogenic shock, refractory hypotension, severe metabolic acidosis, acute respiratory distress syndrome (ARDS), severe cardiac arrhythmias, liver and renal failure, multi-organ failure.
  • Strychnine: Rhabdomyolysis, hyperthermia, lactic acidosis, respiratory arrest due to muscle paralysis, cerebral hypoxia from prolonged seizures.
• Long-term:
  • ARs: Chronic anemia, organ damage from prior hemorrhage.
  • Bromethalin: Persistent neurological deficits (e.g., ataxia, paresis, cognitive impairment).
  • Cholecalciferol: Chronic kidney disease, irreversible nephrocalcinosis, secondary hyperparathyroidism.
  • Zinc Phosphide: Chronic organ damage (cardiac, hepatic, renal) in survivors.
  • Strychnine: Anoxic brain injury if respiratory arrest was prolonged.

Prognosis

• Factors:
  • Type of Rodenticide: Superwarfarins and phosphides generally carry a worse prognosis than first-generation anticoagulants or small cholecalciferol ingestions.
  • Dose Ingested: Higher doses are associated with worse outcomes.
  • Time to Treatment: Prompt decontamination and administration of antidotes/supportive care significantly improve prognosis.
  • Patient Age and Comorbidities: Very young, elderly, or patients with underlying organ dysfunction (e.g., liver disease for ARs, renal disease for cholecalciferol) have poorer prognoses.
  • Intent: Intentional ingestions tend to involve larger doses and multiple substances, leading to higher morbidity and mortality.
• Survival: Varies widely by toxin.
  • Anticoagulant Rodenticides: Generally good prognosis with timely Vitamin K administration, even for superwarfarins, though treatment may be prolonged. Mortality is low unless there is severe, untreated hemorrhage (e.g., intracranial).
  • Bromethalin: Prognosis can be poor with large ingestions, leading to severe neurological damage or death.
  • Cholecalciferol: Prognosis is generally good if hypercalcemia is managed aggressively, but severe renal damage can lead to chronic kidney disease.
  • Zinc Phosphide / Aluminum Phosphide: These are among the most lethal rodenticides, with reported mortality rates ranging from 30% to over 60% in severe cases, even with aggressive treatment, due to rapid multi-organ failure.
  • Strychnine: Rapid onset and severe spasms can quickly lead to respiratory arrest. Prognosis is good if prompt intubation, neuromuscular blockade, and benzodiazepine administration control spasms and prevent anoxia.
• Quality of Life: Survivors of severe poisonings may experience long-term organ damage (e.g., chronic kidney disease, neurological deficits), requiring ongoing medical care and impacting quality of life. Psychiatric support is crucial for survivors of intentional ingestions.

Prevention

• Primary: Preventing initial occurrence.
  • Safe Storage: Store all rodenticides in their original, labeled, child-resistant containers in locked cabinets or areas inaccessible to children, pets, and vulnerable individuals.
  • Product Selection: Encourage use of less toxic alternatives (e.g., traps) where feasible. If rodenticides must be used, choose formulations that are less attractive to children/pets (e.g., bait stations).
  • Public Education: Campaigns on the dangers of rodenticides, proper use, storage, and disposal.
  • Integrated Pest Management: Emphasize non-chemical methods first (e.g., sealing entry points, eliminating food sources).
• Secondary: Early detection and intervention to minimize harm after exposure.
  • Prompt Consultation: Immediate contact with a poison control center (e.g., 1-800-222-1222 in the US) upon suspected exposure.
  • Emergency Preparedness: Knowing where the nearest emergency care facility is and what information to provide.
  • Observation: Close monitoring for symptom development after minor exposures, especially with superwarfarins (delayed effects).
• Tertiary: Preventing complications and long-term sequelae.
  • Aggressive Medical Management: Timely and appropriate treatment of poisoning to prevent organ damage.
  • Rehabilitation: Physical, occupational, and speech therapy for neurological or functional deficits.
  • Psychiatric Follow-up: For individuals with intentional self-harm.
  • Education on Recurrence Prevention: Reinforcing safe storage practices post-hospitalization.

Special Populations

• Pediatric:
  • Increased Vulnerability: Children are more susceptible to toxic effects due to smaller body size, higher metabolic rates, and immature organ systems.
  • Common Route: Accidental ingestion is the predominant route.
  • Dose: Even small "taste" ingestions of highly potent rodenticides (e.g., superwarfarins, bromethalin) can be significant.
  • Management: Decontamination is similar, but dosages of medications (e.g., Vitamin K1, activated charcoal) are weight-based. Close monitoring for delayed symptoms is crucial. Psychological assessment for underlying behavioral issues in the home environment may be warranted.
• Geriatric:
  • Polypharmacy: Increased risk of drug-drug interactions (e.g., ARs with other anticoagulants, NSAIDs).
  • Comorbidities: Pre-existing conditions (renal, hepatic, cardiovascular disease) can worsen outcomes and alter drug metabolism/excretion.
  • Decreased Physiological Reserve: Less tolerance to shock, fluid shifts, and organ damage.
  • Cognitive Impairment: May make accurate history taking difficult and increase risk of accidental re-exposure.
• Pregnancy:
  • Risk to Fetus: Many rodenticides can be teratogenic or cause fetal harm.
    • Anticoagulant Rodenticides: First-generation anticoagulants like warfarin are teratogenic (fetal warfarin syndrome). Superwarfarins also cross the placenta and can cause fetal bleeding. Vitamin K1 is generally safe in pregnancy. PCC can be used.
    • Cholecalciferol: Severe hypercalcemia can be detrimental to fetal development.
    • Phosphides: Can cause fetal toxicity.
  • Management Modifications: Careful consideration of antidote choice and supportive treatments to minimize fetal exposure while treating the mother. Consult with toxicology and obstetrics.
• Comorbidities:
  • Liver Disease: Exacerbates coagulopathy from ARs, impairs metabolism of many toxins.
  • Renal Disease: Impairs excretion of toxins and their metabolites, worsens hypercalcemia from cholecalciferol.
  • Bleeding Disorders: Pre-existing coagulopathies make AR toxicity much worse.
  • Cardiac Disease: Patients with pre-existing heart conditions are more vulnerable to cardiac arrhythmias and shock caused by phosphides or severe hypercalcemia.
  • Neurological Disorders: Pre-existing seizure disorders may lower the threshold for bromethalin or strychnine-induced seizures.

Clinical Pearls

• Diagnostic:
  • Always suspect superwarfarin ingestion if the patient presents with unexplained bleeding and a prolonged PT/INR that is poorly responsive to standard Vitamin K doses. Obtain a thorough environmental history.
  • Phosphide poisoning should be considered in patients with rapid-onset severe GI upset, metabolic acidosis, shock, and a "garlic" or "rotten fish" odor on breath/vomitus.
  • Neurological symptoms (seizures, ataxia, paralysis, severe spasms) are red flags for bromethalin or strychnine.
  • Delayed onset of symptoms is common, especially with anticoagulant and cholecalciferol rodenticides. Do not assume "no symptoms" means "no toxicity."
  • Obtain the product packaging whenever possible to confirm the active ingredient and concentration.
• Treatment:
  • Contact Poison Control Immediately (1-800-222-1222 in the US) for all suspected rodenticide ingestions, regardless of symptom severity.
  • Vitamin K1 (phytonadione) is the antidote for anticoagulant rodenticides. For superwarfarins, treatment duration can be months and guided by INR.
  • Decontamination with activated charcoal should be considered early if within 1-2 hours for most ingestions, but is controversial for phosphides. Never induce emesis.
  • Do NOT use water or acidic solutions for gastric lavage in phosphide ingestions, as this promotes phosphine gas release.
  • Aggressive supportive care is the mainstay for most non-anticoagulant rodenticides.
  • Be prepared for severe neurological events (seizures, respiratory arrest) in bromethalin and strychnine poisonings.
  • Manage hypercalcemia aggressively with IV fluids, furosemide, calcitonin, and bisphosphonates for cholecalciferol toxicity.
• Pitfalls:
  • Underestimating the toxicity of superwarfarins in asymptomatic patients.
  • Delayed diagnosis due to non-specific symptoms or delayed onset.
  • Inadequate duration of Vitamin K1 therapy for superwarfarins, leading to relapse.
  • Failure to protect personnel from phosphine gas during management of phosphide poisoning.
  • Over-reliance on toxicology screens, which often do not detect specific rodenticides.
  • Assuming small ingestions in children are always benign without proper evaluation and observation.

Recent Updates

• Guidelines: Ongoing emphasis on safe storage and integrated pest management strategies to reduce exposures. Recommendations for aggressive Vitamin K1 dosing and prolonged treatment for superwarfarin ingestions remain consistent.
• Evidence: Research continues to explore the exact mechanisms of toxicity and potential novel therapeutic targets for some of the less common or highly lethal rodenticides (e.g., phosphides). Studies on the long-term neurological and renal sequelae in survivors are also important.
• Controversies:
  • Role of multi-dose activated charcoal: While potentially beneficial for highly lipid-soluble and enterohepatically recirculated toxins like superwarfarins and bromethalin, evidence for improved outcomes is not uniformly strong, and risks of aspiration must be weighed.
  • Gastric lavage for phosphides: Highly controversial due to risk of phosphine gas release and lack of clear benefit; generally not recommended.
  • Specific antidotes for non-anticoagulant rodenticides: Ongoing search for specific antagonists or better neuroprotective agents for bromethalin and strychnine, or direct agents to neutralize phosphine gas.

Key References

• Guidelines:
  • American Academy of Pediatrics (AAP) and American Association of Poison Control Centers (AAPCC) guidelines for managing common pediatric toxic exposures.
  • World Health Organization (WHO) guidelines on pesticide poisoning management.
  • Clinical practice guidelines from major toxicology societies (e.g., American College of Medical Toxicology - ACMT).
• Studies:
  • Relevant original research articles published in journals such as Clinical Toxicology, Journal of Medical Toxicology, Annals of Emergency Medicine, Pediatrics.
  • Retrospective analyses of poison control center data for epidemiological trends and outcome evaluations.
• Reviews:
  • UpToDate sections on specific rodenticide poisonings.
  • Textbooks: Goldfrank's Toxicologic Emergencies, Poisoning & Drug Overdose (Olson).
  • Review articles in toxicology journals.